Evogene Secures $3.4M via $1.00 Warrant Inducement, Issues $1.25 Warrants
Evogene will receive $3.4 million from the exercise of 1,692,308 Series A and B warrants at $1.00 each. In exchange, the investor gains unregistered Series A-1 and B-1 warrants for 2,538,462 shares each at $1.25, exercisable immediately and expiring in 18 months to five years.
1. Transaction Overview
Evogene has entered into a warrant inducement agreement with an institutional investor for the immediate exercise of 1,692,308 Series A and 1,692,308 Series B warrants at $1.00 per share, generating approximately $3.4 million in gross proceeds before fees.
2. New Warrants Issuance
In consideration for the full exercise of the existing warrants, the investor will receive unregistered Series A-1 warrants to purchase up to 2,538,462 ordinary shares at $1.25 and Series B-1 warrants for 2,538,462 shares at $1.25, exercisable immediately and expiring five years and 18 months after issuance, respectively.
3. Use of Proceeds and Closing Conditions
Evogene intends to use the net proceeds for working capital and general corporate purposes. The closing of the transaction is expected on or about February 11, 2026, subject to customary closing conditions, with A.G.P./Alliance Global Partners acting as sole financial advisor.